CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


CCPWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug2657 Virtual-Care Cognitive Behavioural Therapy Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D001008 Anxiety Disorders NIH 0.17

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19

This study will provide investigational convalescent plasma for patients infected with the SARS-CoV-2 with mild to moderate symptoms who meet inclusion criteria as judged by physician evaluation.

NCT04438057 COVID-19 Biological: CCP

Primary Outcomes

Description: a. Time to resolution of symptoms will be defined as time from randomization (day 0) to a successful outcome. c. A successful outcome is defined as symptom improvement of 3 numbers or down to zero on the memory aid for all symptoms noted.

Measure: Time to Resolution of Symptoms

Time: 28 days

Measure: SAEs within 24 hours of plasma infusion

Time: 28 days

Secondary Outcomes

Description: A 50% decrease at day 28 in C-Reactive Protein (mg/mL)

Measure: Decrease in Inflammatory Markers

Time: 28 days

Description: A 50% decrease at day 28 in D-Dimer (ng/mL)

Measure: Decrease in Inflammatory Markers

Time: 28 days

Description: A 50% decrease at day 28 in Ferritin (ng/mL)

Measure: Decrease in Inflammatory Markers

Time: 28 days

Description: A 50% decrease at day 28 in Lactate Dehydrogenase (U/L)

Measure: Decrease in Inflammatory Markers

Time: 28 days

Measure: Hospitalization within 28 days

Time: 28 days


No related HPO nodes (Using clinical trials)